Stock Events

Stock Events

Miro Sciences 

A$0.051000
0
+A$0.00+2% 03:38 Today

Statistics

Day High
0.051
Day Low
0.05
52W High
0.18
52W Low
0.041
Volume
160,513
Avg. Volume
155,060
Mkt Cap
19.88M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-4.69MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap37.49B
Biogen focuses on neurodegenerative diseases, similar to NSB's focus on neurological disorders.
Lilly(Eli) &
LLY
Mkt Cap1.26T
Eli Lilly has a strong portfolio in Alzheimer's disease treatments, directly competing with NSB's Alzheimer's projects.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG has significant investments in neuroscience and Alzheimer's disease, overlapping with NSB's research areas.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has a history of developing treatments for neurological conditions, competing in the same therapeutic area as NSB.
Novartis
NVS
Mkt Cap303.67B
Novartis offers several products for neurological conditions, making it a direct competitor in the neurology sector.
Merck
MRK
Mkt Cap368.89B
Merck & Co. is involved in developing therapies for Alzheimer's disease, which is a key area for NSB.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie has a growing interest in neurodegenerative diseases, particularly Alzheimer's, competing with NSB's focus.
AMGEN
AMGN
Mkt Cap251.94B
Amgen has research initiatives in neuroscience, including Alzheimer's disease, positioning it as a competitor to NSB.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson conducts extensive research in neuroscience, making it a competitor in the neurological space.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca has a dedicated neuroscience R&D unit, which competes with NSB in developing neurological disorder treatments.

About

Established in 2002 and headquartered in Cottesloe, Australia, NeuroScientific Biopharmaceuticals Limited specializes in the development of medical therapies for neurodegenerative conditions. The company conducts extensive preclinical and clinical research utilizing its proprietary technological platforms to advance these treatments. Its primary pharmaceutical compound, EmtinB, is being developed as a potential therapeutic agent for diseases including neurodegenerative dementia, Alzheimer's disease, and various degenerative disorders affecting the optic nerve.
Show More
CEO
Nathan Smith
Employees
9
Country
Australia
ISIN
AU0000496887
WKN
000A3DPPS

Listings

AU
AU
NSB.AU
AU
AU
MSX.AU
F
DE
NBM0.F

0 Comments

Share your thoughts

FAQs

What is Miro Sciences stock price today?▼
The current price of MSX.AU is A$0.05 AUD — it has increased by +2% in the past 24 hours. Watch Miro Sciences stock price performance more closely on the chart.
What is Miro Sciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Australia Exchange exchange Miro Sciences stocks are traded under the ticker MSX.AU.
What is Miro Sciences market cap?▼
Today Miro Sciences has the market capitalization of 19.88M
What is Miro Sciences revenue for the last year?▼
Miro Sciences revenue for the last year amounts to 0 AUD.
What is Miro Sciences net income for the last year?▼
MSX.AU net income for the last year is -4.69M AUD.
How many employees does Miro Sciences have?▼
As of November 2, 2026, the company has 9 employees.
In which sector is Miro Sciences located?▼
Miro Sciences operates in the Health & Wellness sector.
When did Miro Sciences complete a stock split?▼
Miro Sciences has not had any recent stock splits.
Where is Miro Sciences headquartered?▼
Miro Sciences is headquartered in Perth, Australia.